Centaur Pharmaceuticals Overview
- Status
-
Acquired/Merged
- Latest Deal Type
-
M&A
Centaur Pharmaceuticals General Information
Description
Developer of novel class of small molecule pharmaceutical compounds for the treatment of neurodegenerative and inflammatory diseases. The company develops such compounds to treat inflammatory diseases such as acute stroke, dementia, rheumatoid arthritis, myocardial ischemia and Parkinson's disease.
Contact Information
Corporate Office
- 1220 Memorex Drive
- Santa Clara, CA 95050
- United States
Corporate Office
- 1220 Memorex Drive
- Santa Clara, CA 95050
- United States
Centaur Pharmaceuticals Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 6. Merger/Acquisition | 12-Dec-2002 | Completed | Clinical Trials - Phase 3 | |||
| 5. Later Stage VC | 09-Jul-2002 | Completed | Generating Revenue | |||
| 4. Later Stage VC | 13-Mar-2000 | Completed | Generating Revenue | |||
| 3. Early Stage VC | 01-Dec-1994 | Completed | Product Development | |||
| 2. Early Stage VC (Series B) | 12-Jul-1993 | $3.5M | $4.5M | Completed | Generating Revenue | |
| 1. Angel (individual) | 01-Jan-1991 | $1M | $1M | Completed | Startup |
Centaur Pharmaceuticals Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | 2,545,454 | $0.001000 | $1.38 | $1.38 | 1x | $1.38 | 8.48% | |
| Series A | 2,000,000 | $0.001000 | $0.5 | $0.5 | 1x | $0.5 | 6.67% |
Centaur Pharmaceuticals Patents
Centaur Pharmaceuticals Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2002253857-A1 | Use of aryl nitrone compounds in methods for treating neuropathic pain | Inactive | 08-Jan-2001 | ||
| US-6479697-B2 | By the reaction of the corresponding disulfophenyl aldehyde with n-tert-butylhydroxylammonium acetate | Inactive | 10-Jan-2000 | ||
| US-20020128318-A1 | By the reaction of the corresponding disulfophenyl aldehyde with n-tert-butylhydroxylammonium acetate | Active | 10-Jan-2000 | ||
| US-6689911-B2 | Condensation reaction of a benzylaldehyde with n-tert-butylhydroxylamine, large scale production | Inactive | 10-Jan-2000 | ||
| US-20030069442-A1 | Condensation reaction of a benzylaldehyde with n-tert-butylhydroxylamine, large scale production | Active | 10-Jan-2000 | C07C303/32 |
Centaur Pharmaceuticals Former Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Cycad Group | Venture Capital | Minority |
Centaur Pharmaceuticals Acquisitions (1)
Centaur Pharmaceuticals’s most recent deal was a Merger/Acquisition with CentaurVA Animal Health. The deal was made on 01-Jan-1999.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| CentaurVA Animal Health | 01-Jan-1999 | Merger/Acquisition | Pharmaceuticals |
Centaur Pharmaceuticals FAQs
-
Where is Centaur Pharmaceuticals headquartered?
Centaur Pharmaceuticals is headquartered in Santa Clara, CA.
-
What industry is Centaur Pharmaceuticals in?
Centaur Pharmaceuticals’s primary industry is Pharmaceuticals.
-
Is Centaur Pharmaceuticals a private or public company?
Centaur Pharmaceuticals is a Private company.
-
What is Centaur Pharmaceuticals’s current revenue?
The current revenue for Centaur Pharmaceuticals is .
-
How much funding has Centaur Pharmaceuticals raised over time?
Centaur Pharmaceuticals has raised $37.2M.
-
Who are Centaur Pharmaceuticals’s investors?
Cycad Group has invested in Centaur Pharmaceuticals.
-
When was Centaur Pharmaceuticals acquired?
Centaur Pharmaceuticals was acquired on 12-Dec-2002.
-
Who acquired Centaur Pharmaceuticals?
Centaur Pharmaceuticals was acquired by Renovis.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
